10-Q: Kiromic BioPharma Reports First Quarter 2024 Results, Cites Going Concern Uncertainty
Sentiment:
Quarterly Report
Kiromic BioPharma's Q1 2024 results show a net loss of $6.1 million and raise substantial doubt about the company's ability to continue as a going concern due to insufficient cash.
Delay expectedThe company has experienced delays in the past with its IND applications, as evidenced by the clinical holds placed by the FDA.The company's development timeline is relatively slow compared to other companies in the cell therapy space.
Capital raiseThe company is actively exploring various financing strategies, including additional funding from current or new investors, inclusive of a potential public offering of equity.The company is working with a financial advisor to assist it with its efforts to obtain financing.The company has issued senior secured convertible promissory notes to raise capital.
Worse than expectedThe company's cash position is insufficient to meet its obligations beyond July 2024, raising substantial doubt about its ability to continue as a going concern.The company reported a net loss of $6.1 million for Q1 2024, which is worse than the $5.3 million loss in the same period of 2023.The company's accumulated deficit of $129 million as of March 31, 2024, is a significant concern.
Summary
- Kiromic BioPharma reported a net loss of $6.1 million for the first quarter of 2024, compared to a $5.3 million loss in the same period of 2023.
- The company's research and development expenses increased to $3.0 million, up from $2.1 million in the prior year, driven by the development of Deltacel.
- General and administrative expenses decreased to $2.1 million from $2.7 million year-over-year, primarily due to reduced legal and professional fees.
- The company's cash and cash equivalents stood at $3.7 million as of March 31, 2024, and management anticipates that existing cash resources will not be sufficient to meet operating and liquidity needs beyond July 2024.
- Kiromic has a significant accumulated deficit of $129 million as of March 31, 2024.
- The company is exploring various financing strategies, including additional funding from current or new investors, but there is no assurance that these efforts will be successful.
- The company's first clinical trial, Deltacel-01, is ongoing with early results showing stabilization of disease and tumor reduction in some patients.
Sentiment
Score: 3
Explanation: The document indicates significant financial distress and uncertainty about the company's future, despite some positive clinical trial results. The going concern warning and the need for immediate financing are major negative factors.
Positives
- The Deltacel-01 clinical trial has shown early signs of positive outcomes, including disease stabilization and tumor reduction in some patients.
- The company has activated multiple clinical trial sites for the Deltacel-01 study.
- General and administrative expenses decreased by 23% year-over-year, indicating some cost control measures.
- The company is actively exploring financing options to address its liquidity concerns.
Negatives
- The company reported a net loss of $6.1 million for Q1 2024.
- The company has an accumulated deficit of $129 million as of March 31, 2024.
- The company's cash and cash equivalents are insufficient to meet operating needs beyond July 2024.
- There is substantial doubt about the company's ability to continue as a going concern.
- The company is reliant on securing additional financing, with no guarantee of success.
- Research and development expenses increased by 46% year-over-year.
Risks
- The company's current cash position is insufficient to meet its obligations beyond July 2024, raising substantial doubt about its ability to continue as a going concern.
- The company is dependent on securing additional financing, which may not be available or may be on unfavorable terms.
- The company's research and development programs are subject to delays and uncertainties, including clinical trial enrollment and regulatory approvals.
- The company faces risks related to the development and commercialization of its product candidates, including competition and market acceptance.
- The company is subject to legal proceedings, including ongoing litigation related to past disclosures and agreements.
- The company's financial results are subject to fluctuations and may be affected by various factors, including economic conditions and industry trends.
Future Outlook
The company plans to continue the development of Isocel and Procel and expects to submit INDs by the first half of 2025, subject to obtaining sufficient financing. The company is also considering applying for Fast Track designation for Deltacel and potentially Breakthrough Therapy Designation in 2025.
Management Comments
- Management anticipates that existing cash resources will not be sufficient to meet operating and liquidity needs beyond July 2024.
- Management is evaluating different strategies to obtain the required funding of future operations.
- Management may further evaluate additional cost reduction actions, including additional reductions in the company's workforce and delay of research and development expenditures on one or more product candidates, in order to reduce the company's current expenditures and preserve cash.
Industry Context
The company is operating in the competitive field of cell therapy, specifically targeting solid tumors. The company's approach of using allogeneic Gamma Delta T-cells and proprietary engineering methods is aimed at addressing the limitations of current cell therapies. The company's focus on solid tumors is a significant area of unmet need in cancer treatment.
Comparison to Industry Standards
- Kiromic's financial situation is concerning, as many biotech companies at this stage of development are not profitable, but they typically have a longer cash runway.
- The company's cash burn rate is high, and the need for additional financing is urgent.
- The early clinical data from the Deltacel-01 trial is promising, but it is still very early in the development process.
- The company's reliance on convertible promissory notes for financing is a high-risk strategy, as it can lead to significant dilution for existing shareholders.
- Compared to other companies in the cell therapy space, Kiromic's development timeline is relatively slow, and the company has faced regulatory hurdles with its IND applications.
- Companies like Allogene Therapeutics and CRISPR Therapeutics are also developing allogeneic cell therapies, but they have significantly more funding and are further along in clinical development.
Management Changes
| Role | Previous Person | New Person | Effective Date | Reason |
|---|---|---|---|---|
| Chief Executive Officer | Maurizio Chiriva-Internati | Pietro Bersani | 2022-01-27 | Termination for cause |
| Chief of Staff | Chief Medical Officer and Head of Clinical | Scott Dahlbeck | 2022-02-09 | Title change |
| Chief Strategy and Innovation Officer | Gianluca Rotino | Consultant | 2022-02-09 | Transition to consulting role |
| Director | Frank Tirelli | 2022-11-16 | Resignation | |
| Director | Karen Reeves | 2022-12-06 | Resignation |
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Disclosure Committee Formation | The Board approved the formation of a Disclosure Committee to ensure accurate and timely corporate disclosures. | 2022-01-10 | Improved oversight of corporate disclosures. |
| Vetting Process Changes | The company implemented changes to its vetting process for prospective director and officer candidates, including thorough background checks. | 2022-02-02 | Reduced risk of inaccurate information from candidates. |
Legal Proceedings
- The company is involved in ongoing litigation with Jason Terrell, a former consultant and director.
- The company has settled a class action lawsuit related to a public offering in 2021.
Stakeholder Impact
- Shareholders face significant risk due to the company's financial instability and potential for dilution.
- Employees may be affected by potential workforce reductions and delays in research and development programs.
- Customers (potential patients) may experience delays in the development of new therapies.
- Suppliers and creditors face increased risk due to the company's financial difficulties.
Next Steps
- The company plans to continue the development of Isocel and Procel and expects to submit INDs by the first half of 2025, subject to obtaining sufficient financing.
- The company is considering applying for Fast Track designation for Deltacel.
- The company is exploring various financing strategies to secure additional capital.
- The company will continue to enroll patients in the Deltacel-01 clinical trial and monitor their progress.
Key Dates
| Date | Description |
|---|---|
| 2021-03-22 | Date of Jason Terrell's claim against the company. |
| 2021-06-16 | FDA communicated clinical hold on IND applications. |
| 2021-06-17 | FDA communicated clinical hold on IND applications. |
| 2021-07-02 | Company consummated a public offering of $40 million of common stock. |
| 2021-07-13 | Company received formal clinical hold letters from the FDA. |
| 2022-01-27 | Maurizio Chiriva-Internati terminated as CEO. |
| 2022-01-28 | Frank Tirelli appointed to the Board. |
| 2022-02-02 | Special Committee reported results of Internal Review to the Board. |
| 2022-02-10 | Modification to Employment Agreement with Dr. Scott Dahlbeck. |
| 2022-02-14 | Karen Reeves appointed to the Board. |
| 2022-08-05 | Ronald H. Karp filed a class action complaint. |
| 2022-08-07 | Company entered into a term sheet to settle the class action. |
| 2022-10-03 | Joseph Podmore filed a class action complaint. |
| 2022-10-13 | Company entered into a Standby Equity Purchase Agreement. |
| 2022-11-16 | Frank Tirelli resigned from the Board. |
| 2022-12-06 | Karen Reeves resigned from the Board. |
| 2023-03-28 | Company entered into an Exchange Agreement to convert $8 million of promissory notes into preferred stock. |
| 2023-04-02 | Company issued 8,000 shares of Series C Stock. |
| 2023-04-28 | FDA authorized the company to proceed with the Deltacel-01 study. |
| 2023-05-24 | Company exercised a Commitment increase under the SEPA. |
| 2023-06-02 | Company exercised an additional Commitment increase under the SEPA. |
| 2023-07-18 | Company entered into an Exchange Agreement to convert $6 million of promissory notes into preferred stock and issued 6,000 shares of Series C Stock. |
| 2023-09-29 | Counsel for plaintiffs submitted the proposed settlement materials to the Court for approval. |
| 2023-10-23 | Company entered into a clinical trial agreement with Beverly Hills Cancer Center. |
| 2023-12-13 | First patient in the Deltacel-01 trial received the first dose of Deltacel. |
| 2024-01-31 | Chancery Court issued a letter opinion dismissing Terrell's claims. |
| 2024-02-28 | Company activated a second clinical trial site with Virginia Oncology Associates. |
| 2024-03-11 | Chancery Court entered a stipulated form of Final Order and Judgment, dismissing Terrell's claims. |
| 2024-03-28 | Company entered into an Exchange Agreement to convert $8 million of promissory notes into preferred stock and issued 8,000 shares of Series D Stock. |
| 2024-04-02 | Company issued a $2 million senior secured convertible promissory note. |
| 2024-04-08 | Company activated the third site in the Deltacel-01 trial, Texas Oncology. |
| 2024-05-01 | Company issued a $2 million senior secured convertible promissory note. |
| 2024-05-08 | Company activated its fourth clinical trial site, UPMC Hillman Cancer Center. |
| 2024-05-09 | Terrell's opening appellate brief is due. |
| 2024-05-14 | Beneficial ownership limitation on convertible notes increases to 19.99%. |
Keywords
Kiromic BioPharma, Gamma Delta T-cell therapy, Deltacel, Isocel, Procel, clinical trial, biotherapeutics, going concern, financing, net loss, research and development, cancer therapy
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.